Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications
CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm's PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications where bone marrow may be suppressed, such as radiation and chemotherapy. Additionally, work done in animals using PLX cells in Acute Radiation Sickness (ARS) provides another data point to approach that PLX cells can be administered locally into skeletal muscle, distant to...
Comunicato Precedente
Comunicato Successivo
New York,
(informazione.news - comunicati stampa - varie)
CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm's
PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications where bone marrow may be suppressed, such as radiation and chemotherapy.
Additionally, work done in animals using PLX cells in Acute Radiation Sickness (ARS) provides another data point to approach that PLX cells can be administered locally into skeletal muscle, distant to the target organ, and obtain efficacious systemic effects.
Pluristem received U.S. Food and Drug Administration (FDA) clearance to begin a Phase II clinical trial using PLX-PAD intramuscularly for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). The trial will evaluate the safety and efficacy of two doses (150x106 cells and 300x106 cells) of PLX-PAD versus placebo administered via one or two intramuscular (IM) injections. The study population will be comprised of IC patients, Fontaine class IIb; Rutherford category 2-3 and will be conducted at several leading U.S. clinical sites.
Recently the compassionate use of Pluristem's PLX Cells saved the life of a child after a bone marrow transplantation failure failed.
Source: http://yhoo.it/JpzxT0
Copyright Thomson Reuters
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: %s via Thomson Reuters ONE
[HUG#1614350]
Per maggiori informazioni
Sito Web
http://
Ufficio Stampa
Thomson Reuters (Leggi tutti i comunicati)
3 Times Square
10036 New York, NY
;
